Exercise to Fight Obesity (ExFO)

May 31, 2025 updated by: Paolo Rossetti, Instituto de Investigacion Sanitaria La Fe

Impact of a Structured Physical Exercise Program on Body Composition in Morbid Obesity: A Randomized Controlled Trial

This clinical trial aims to determinate whether a structured exercise program, supported by telerehabilitation, can help individuals with severe obesity who are going to undergo bariatric surgery.

The main objective of this study is whether a structured exercise program, including both supervised and home-based workouts, leads to greater body fat loss and improved strength compared to usual care. Furthermore, it also aims to evaluate other potentially affected aspects, such as body composition and functionality, quality of life, cardiovascular fitness, and various genetic and metabolic factors.

This study is a randomized clinical trial with two groups:

  • The intervention group will follow a structured exercise program both pre- and post- surgery.
  • The control group will receive standard care, including nutritional counseling and general health advice.

The study will include 72 adults with severe obesity (36 men and 36 women), all of whom will be randomly assigned to either the intervention or control group.

Participants in the exercise group will follow these steps:

  1. Before Surgery (Prehabilitation): A 26-week program with aerobic and strength exercises, done in-person or remotely 2-4 times per week.
  2. Pre-Surgery Maintenance: A flexible period before surgery where participants continue exercising on their own.
  3. After Surgery (Rehabilitation): A 20-week program focused on recovery and strength.
  4. Post-Surgery Maintenance: A long-term, self-guided phase to maintain progress.

Participants in the exercise group will also receive the same care as the control group, including nutrition counseling and medical checkups.

To evaluate participant progress, a series of measurements will be carried out, including:

  • BMI and body composition
  • Physical function assessed through isometric strength tests and other measures such as the Sit-to-Stand test and the 6-Minute Walk Test
  • Quality of life and lifestyle assessed using validated questionnaires
  • Daily physical activity measured with pedometers
  • Metabolic and genetic analysis from blood samples

If proven effective, this program could help establish structured exercise with telerehabilitation as a standard component of obesity care. The results may support the integration of exercise programs into clinical practice, leading to improved long-term outcomes for individuals with severe obesity undergoing bariatric surgery. Additionally, insights into genetic and metabolic factors may contribute to the development of personalized treatment strategies.

Study Overview

Detailed Description

INTRODUCTION Severe obesity represents a growing public health challenge in Spain, with a marked increase in prevalence and significant implications for morbidity, mortality, and healthcare expenditure. In 2022, nearly 400,000 individuals were affected by class III obesity, reflecting an increase of more than 200% since the 1990s. This condition is strongly associated with serious comorbidities, including cardiovascular disease, type 2 diabetes, and certain cancers, and is linked to a substantial reduction in life expectancy. From an economic perspective, overweight and obesity are estimated to account for approximately 10% of national healthcare costs, with severe obesity contributing significantly through both direct medical expenses and indirect costs related to productivity loss.

Conventional treatment strategies, such as dietary interventions and physical activity (PA), offer limited long-term effectiveness in individuals with severe obesity. Although physical exercise (PE)-a structured form of PA-has shown benefits beyond weight reduction, including improvements in body composition and cardiorespiratory fitness, the majority of participants find it difficult to sustain behavioral changes over time. Furthermore, the degree of weight loss required in this population frequently exceeds what lifestyle interventions alone can achieve.

Bariatric surgery has emerged as an effective alternative, providing substantial short-term weight reduction and improvement in obesity-related comorbidities. However, it is not without limitations, including the loss of lean body mass and the risk of long-term weight regain, particularly in the absence of adequate PA following surgery. Recent studies have shown that postoperative PE programs may improve these outcomes, although the evidence on the benefits of preoperative exercise (prehabilitation) remains limited.

In this context, telerehabilitation appears to be a promising strategy for enhancing accessibility, adherence, and continuity of care. Remote supervision of structured exercise programs, supported by wearable technologies such as activity trackers, may help overcome common barriers and increase participant engagement. Additionally, the substantial variability in individual responses to obesity treatment highlights the need for personalized interventions. Genetic, metabolic, and epigenetic factors likely contribute to treatment resistance in certain individuals, and the identification of predictive biomarkers may help guide more effective and individualized obesity management strategies.

OBJECTIVES:

Primary Objective To evaluate whether a structured PE and PA promotion program, incorporating both supervised in-person and home-based sessions through telerehabilitation tools, is more effective than standard care guidelines in reducing fat percentage and increasing lower-limb strength in candidates for bariatric surgery.

Secondary Objectives

To determine whether the structured PE and PA program is more effective than standard care in achieving:

  1. Improved physical functionality.
  2. Greater cardiovascular capacity.
  3. Enhanced quality of life.
  4. Superior outcomes in other body composition variables.

Additional secondary objectives include:

  1. Evaluating adherence to the recommended session frequency and prescribed training volume.
  2. Analyzing the relative contribution, adjusted for sex, of fat percentage reduction and lower-limb strength improvement to functionality and quality of life.
  3. Assessing the effects of the PE and PA program on plasma levels of adipokines, exerquines, and cytokines.
  4. Investigating epigenetic modifications induced by the PE program.
  5. Identifying differences in metabolic, genetic, and epigenetic profiles according to physical fitness level and total volume of PE and PA performed (stratified by activity level, independent of group allocation).
  6. Exploring associations between body composition and functional variables with metabolic, genetic, and epigenetic factors.

METHODOLOGY The methodology of the study is included in the initial summary and detailed in the subsequent sections (study design, arms and interventions, outcomes measures and elegibility) .

SAMPLE SIZE The sample size for this clinical trial was determined based on the two coprimary outcomes: fat percentage and lower-limb strength. For fat percentage, the calculation aimed to detect a 2% reduction in the experimental group compared to the control group, with 80% statistical power and a 5% significance level, resulting in an estimated minimum of 13 participants per group. Similarly, for lower-limb strength, assessed via the 5-repetition Sit-to-Stand (5STS) test, a 30% improvement was considered clinically relevant, requiring only 6 participants per group under the same statistical assumptions.

Given that the variable with the higher sample size requirement was fat percentage, it was used to guide the final sample size. To allow for subgroup analyses by sex, the study was designed to include 30 participants per group-15 women and 15 men. To accommodate an anticipated dropout rate of 20%, the final sample size was increased to 36 participants in each group, with equal sex distribution (18 women and 18 men per group).

STATISTICAL METHODS Data management and statistical analyses will be performed using SPSS software. A dedicated study database will be created, and data accuracy will be verified through random cross-checks with original records. Prior to analysis, data cleaning will be conducted to ensure consistency and completeness, followed by the creation of derived variables where necessary.

The analysis will begin with a flowchart of participant progression throughout the study, alongside a comparison of baseline characteristics between groups to assess equivalence at enrollment. Descriptive statistics will be used: categorical variables will be reported as frequencies and percentages, while continuous variables will be expressed as means and standard deviations or medians and interquartile ranges, depending on data distribution.

To evaluate the primary outcomes, a mixed-model ANOVA will be conducted, with time (baseline, end of prehabilitation, and pre-surgery) as the within-subject factor and group allocation (intervention vs. control) as the between-subject factor. The assumptions of normality and homogeneity will be tested using the Shapiro-Wilk and Levene's tests, respectively. When assumptions are violated, appropriate statistical corrections will be applied.

Effect sizes will be reported using partial eta squared (η²), and post hoc analyses will include Bonferroni correction when significant group-time interactions are detected. The magnitude of observed effects will be interpreted using Cohen's d.

The same statistical approach will be applied to secondary outcomes, such as physical function, cardiovascular fitness, quality of life, and body composition. Intervention adherence will be quantified by the proportion of completed sessions and those performed at the prescribed intensity, followed by between-group comparisons using non-parametric tests as appropriate.

To assess the influence of fat mass reduction and improved lower-limb strength on clinically relevant outcomes (e.g., Six-Minute Walk Test [6MWT], Impact of Weight on Quality of Life [IWQOL]), participants will be dichotomized based on whether they achieved a minimally clinically important difference. Multivariate logistic regression models will be constructed, using these two variables and sex as predictors. Model refinement will be carried out via backward elimination, and results will be presented as odds ratios with 95% confidence intervals.

Finally, linear regression models will be used to explore associations between body composition and functional outcomes with genetic, metabolic, and epigenetic markers.

SUBSTUDY 2: POSTOPERATIVE REHABILITATION FOLLOWING BARIATRIC SURGERY In addition to the main study, a subgroup of participants will be enrolled exclusively in the postoperative phase, forming part of Substudy 2. This substudy targets individuals already on the bariatric surgery waiting list and focuses solely on postoperative rehabilitation and maintenance.

The study design and intervention protocols are identical to those of the main study, but the follow-up period is limited to 12 months. Measurements will be conducted at three time points: prior to surgery, 6 months post-surgery, and 12 months post-surgery.

The key differences between the two substudies are as follows:

  • Primary Outcome Measures: Given the exclusive postoperative focus of Substudy 2, the primary endpoints differ from those in the main study:

    • Lean Mass Reduction: Assessed via bioelectrical impedance analysis (BIA), this outcome is prioritized over fat percentage reduction, as substantial fat mass loss is expected in all participants following surgery.
    • Lower-Limb Strength: Evaluated using the Five-Repetition Sit-to-Stand (5STS) test, which serves as a functional indicator of muscular performance and recovery.
  • Sample Size: The sample size was calculated to detect a directional hypothesis of a 25% smaller decrease in lean mass in the experimental group compared to the control group (effect size f = 0.8), with 80% power and a 5% significance level. This calculation yielded a minimum requirement of 15 participants per group.

To allow for sex-based subgroup analyses, each group (intervention and control) must include 30 participants-15 women and 15 men. Considering an expected dropout rate of approximately 15% in this substudy, the final sample size will be increased to 34 participants per group, resulting in a total of 68 participants overall.

Aside from the differences outlined above, all remaining aspects of Substudy 2-including methodology, intervention content, and assessment procedures-will follow the same protocols described in the main study.

Study Type

Interventional

Enrollment (Estimated)

72

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

      • Valencia, Spain, 46026
        • Recruiting
        • Hospital la Fé
        • Contact:
        • Contact:
        • Principal Investigator:
          • Paolo Rossetti, Medicine
        • Sub-Investigator:
          • Pilar Masdeu, Medicine
        • Sub-Investigator:
          • Eva M Gacó Santana, Nutrition
        • Sub-Investigator:
          • Juan Francisco Merino Torres, Medicine
        • Sub-Investigator:
          • Andrea Micó, Nutrition
        • Sub-Investigator:
          • Matilde Rubio, Medicine
        • Sub-Investigator:
          • Angela Durá de Miguel, Nutrition
      • Valencia, Spain, 46010
        • Active, not recruiting
        • Facultad de Fisioterapia, universidad de Valencia

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Age: 18-65 years
  • BMI ≥35 with comorbidities, or ≥40, regardless of comorbidity presence

Exclusion Criteria:

  • Participation in a structured physical exercise program within the past 6 months
  • Presence of musculoskeletal or systemic diseases that prevent participation in a physical exercise program
  • Uncontrolled hypertension
  • Uncontrolled diabetes, particularly in the presence of severe complications (neuropathy and/or diabetic foot, proliferative retinopathy)
  • Uncontrolled or unstable cardiovascular disease (acute myocardial infarction within the past year, angina, heart failure, peripheral artery disease)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Guided physical exercise with telerehabilitation
Participants will engage in structured physical exercises, including both aerobic and strength training, guided and monitored by physiotherapists. These exercises will be performed both in person and remotely with the support of telerehabilitation.
Participants will receive the same standard care as the control group, including the same number of visits with the physician and nutritionist and participation in group sessions. Additionally, they will follow a structured physical exercise program, tailored to individual capabilities, combining aerobic and strength exercises, which will primarily be carried out at home with the assistance of telerehabilitation. Physical exercise will be structured in different phases: prior to surgery (prehabilitation), after surgery (rehabilitation), with maintenance periods in between.
Active Comparator: Common physical exercise recommendations given in routine clinical practice
Participants will receive the usual dietary and physical activity recommendations during medical assessments and group sessions.
Participants will receive the standard intervention provided by the healthcare service, which includes recommendations for physical exercise, physical activity, and healthy eating. This intervention is delivered by the Endocrinology and Nutrition Department at Hospital Universitario y Politécnico La Fe and consists of periodic individual follow-ups (at least three in-person visits per year, both pre- and post-bariatric surgery) by specialized medical staff in Endocrinology and licensed Nutrition and Dietetics professionals. Additionally, it includes five preoperative group sessions focusing on various aspects of healthy nutrition, physical exercise, and physical activity.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Fat mass percentage
Time Frame: Baseline, 6 months, perioperative, 6 moths after and 1 year after
The percentage of fat mass relative to the patient's total body mass, measured using bioelectrical impedance analysis (BIA).
Baseline, 6 months, perioperative, 6 moths after and 1 year after
Lower limb strength
Time Frame: Baseline, 6 months, perioperative, 6 moths after and 1 year after
Measured by the 5 repetitions Sit-To-Stand test (5STS)
Baseline, 6 months, perioperative, 6 moths after and 1 year after

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Weight
Time Frame: Baseline, 6 months, perioperative, 6 moths after and 1 year after
Measured with BIA machine. Units: kilograms
Baseline, 6 months, perioperative, 6 moths after and 1 year after
Height
Time Frame: Baseline

Measured using a stadiometer permanently fixed to a wall to minimize variability between patients.

Units: meters

Baseline
Waist circumference
Time Frame: Baseline, 6 months, perioperative, 6 moths after and 1 year after
Measured with a non-elastic tape measure. Units: centimeters
Baseline, 6 months, perioperative, 6 moths after and 1 year after
Skeletal muscle mass
Time Frame: Baseline, 6 months, perioperative, 6 moths after and 1 year after
Measured using bioelectrical impedance analysis (BIA).
Baseline, 6 months, perioperative, 6 moths after and 1 year after
Lean body mass
Time Frame: Baseline, 6 months, perioperative, 6 moths after and 1 year after
Measured using bioelectrical impedance analysis (BIA).
Baseline, 6 months, perioperative, 6 moths after and 1 year after
Visceral fat area
Time Frame: Baseline, 6 months, perioperative, 6 moths after and 1 year after
Measured using bioelectrical impedance analysis (BIA).
Baseline, 6 months, perioperative, 6 moths after and 1 year after
Blood preasure
Time Frame: Baseline, 6 months, perioperative, 6 moths after and 1 year after
Baseline, 6 months, perioperative, 6 moths after and 1 year after
Isometric muscle strength
Time Frame: Baseline, 6 months, perioperative, 6 moths after and 1 year after
Measured with hand grip, knee extension and elbow flexion. Units: kilograms
Baseline, 6 months, perioperative, 6 moths after and 1 year after
6 minutes walking test (6MWT)
Time Frame: Baseline, 6 months, perioperative, 6 moths after and 1 year after

The 6WMT measures the distance the patient travels in 6 minutes walking as fast as they can.

The total distance walked is recorded in meters. The greater the distance, the better the results.

Baseline, 6 months, perioperative, 6 moths after and 1 year after
Short Performance Physical Battery (SPPB)
Time Frame: Baseline, 6 months, perioperative, 6 moths after and 1 year after

The SPPB consists of three components:

  • Balance tests:: The participant is asked to maintain balance in three positions: side-by-side stance, semi-tandem stance, and full tandem stance, each for up to 10 seconds.
  • Speed test: The time taken to walk 4 meters
  • Chair stand test: The participant is instructed to stand up and sit down from a chair five times as quickly as possible without using their arms. The time taken is recorded.

Each component is scored from 0 to 4 points, with a maximum total score of 12. Higher scores indicate better physical performance. The SPPB is widely used in clinical and research settings for assessing frailty, risk of disability, and physical function.

Baseline, 6 months, perioperative, 6 moths after and 1 year after
VO2max/VO2 peak
Time Frame: Baseline, 6 months, perioperative, 6 moths after and 1 year after
Estimated through 6MWT
Baseline, 6 months, perioperative, 6 moths after and 1 year after
Steps per day
Time Frame: Baseline, 6 months, perioperative, 6 moths after and 1 year after
We will provide patients with pedometers to monitor their daily mobility.
Baseline, 6 months, perioperative, 6 moths after and 1 year after
International Physical Activity Questionnaire (IPAQ):
Time Frame: Baseline, 6 months, perioperative, 6 moths after and 1 year after

The IPAQ collects information on physical activity performed in the last 7 days across three specific types: walking, moderate-intensity activities and vigorous-intensity activities.

Participants are asked to report the frequency (days per week) and duration (minutes per day) of each activity type. The questionnaire also includes a question on time spent sitting, to estimate sedentary behavior.

Physical activity data are converted into Metabolic Equivalent of Task (MET)-minutes/week, allowing categorization of individuals into three levels of physical activity: low, moderate, or high.

Baseline, 6 months, perioperative, 6 moths after and 1 year after
International Sedentary Assessment Tool (ISAT)
Time Frame: Baseline, 6 months, perioperative, 6 moths after and 1 year after
Participants report the average amount of time spent in sedentary behaviors on a typical weekday and weekend day. The questions activities analyze the time spent sitting while doing some activities such as working, transportation, watching television or using screens.
Baseline, 6 months, perioperative, 6 moths after and 1 year after
Short Form-36 Health Survey (SF-36)
Time Frame: Baseline, 6 months, perioperative, 6 moths after and 1 year after

It evaluates eight dimensions of health across physical and mental domains: Physical Function, Physical Role; Bodily Pain; General Health; Vitality; Social Function; Emotional Role and Mental Health.

Each dimension is scored from 0 to 100, with higher scores indicating better health status.

Baseline, 6 months, perioperative, 6 moths after and 1 year after
Impact of Weight on Quality of Life (IWQOL)
Time Frame: Baseline, 6 months, perioperative, 6 moths after and 1 year after

It evaluates the physical, emotional, and social impact of overweight and obesity on daily functioning and well-being. It's grouped into five domains: physical function, self-esteem, sexual life, public distress and work.

Participants rate how true each statement is for them, using a 5-point scale. Minimum value: 31, Maximum value: 155 Higher scores indicate better weight-related quality of life.

Baseline, 6 months, perioperative, 6 moths after and 1 year after
Bariatric Analysis and Reporting Outcome System (BAROS)
Time Frame: 6 months post-surgery and one year post-surgery.

The BAROS assesses different aspects of patients undergoing bariatric surgery, including the percentage of excess weight lost, comorbidities and quality of life.

Each domain is scored and higher scores indicate better outcomes. Minimum value: 0, Maximum value: 48

6 months post-surgery and one year post-surgery.
Number of participants with abnormal laboratory tests results
Time Frame: Baseline, 6 months, perioperative, 6 moths after and 1 year after
Several analytical parameters will be assessed in the participants, including complete blood count, biochemical analysis with electrolytes, renal and hepatic function, glycemic levels and HbA1c, albumin levels, vitamin profile, and markers of iron metabolism. Furthermore, the quantification of various exerkines, adipokines, and cytokines will also be conducted.
Baseline, 6 months, perioperative, 6 moths after and 1 year after
Number of participants with genetic alterations
Time Frame: Baseline (Stored in a biobank for analysis if funding is obtained)

A genetic panel targeting obesity-related genes will be performed if funding is secured. Initially, the samples will be stored in a biobank. The following exons will be analyzed:

ABCC8, ACBD6, ADCY3, ADRB2, AFF4, AKR1C2, ALMS1, ARL6, BBIP1, BBS1, BBS10, BBS12, BBS2, BBS4, BBS5, BBS7, BBS9, BDNF, CEL, CEP164, CEP19, CEP290, CPE, CREBBP, CUL4B, CYP27A1, DNMT3A, DYRK1B, EHMT1, EIF2AK3, ENPP1, EP300, FOXP3, FTO, GCK, GHRL, GLIS3, GNAS, GNB1, HNF1A, HNF1B, HNF4A, IFNGR1, IFT172, IFT27, IFT74, INPP5E, INS, KCNJ11, KDM6A, KIDINS220, KIF7, KMT2D, KSR2, LEP, LEPR, LZTFL1, MAGEL2, MC4R, MEGF8, MKKS, MKRN3, MKS1, MRAP2, MYT1L, NDN, NEUROD1, NEUROG3, NLGN2, NR0B2, NTRK2, P4HTM, PCSK1, PDE4D, PDX1, PGM2L1, PHF6, PHIP, POMC, PPARG, PRKAR1A, PRKN, PRMT7, PTF1A, RAB23, RAD21, RAI1, RFX6, RPS6KA3, SCAPER, SCLT1, SDCCAG8, SETD1B, SETD2, SH2B1, SIM1, SNRPN, STX16, TFAP2B, TMEM67, TRAPPC9, TRIM32, TTC8, TUB, VPS13B, WDPCP, WFS1.

Baseline (Stored in a biobank for analysis if funding is obtained)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Paolo Rossetti, Medicine, IIS La Fe
  • Study Director: Rodrigo Martín, Grupo de investigación Clinimetría y desarrollo tecnológico en ejercicio terapéutico (CLIDET)
  • Study Chair: Pilar Masdeu, Medicine, IIS La Fe
  • Study Chair: Noemí Moreno, CLIDET
  • Study Chair: Ana Belén Crujeiras, Unidad de Epigenómica en el Instituto de Investigación Sanitaria de Santiago (IDIS)
  • Study Chair: Maria Dolores Herranz Lopez, Universidad Miguel Hernández
  • Study Chair: Adrián Escriche, CLIDET
  • Study Chair: Cristina Flor, CLIDET
  • Study Chair: Albert Lecube, Sociedad Española para el Estudio de la Obesidad (SEEDO)
  • Study Chair: Enrique Roche Collado, Universidad Miguel Hernández

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 19, 2025

Primary Completion (Estimated)

December 1, 2028

Study Completion (Estimated)

April 1, 2029

Study Registration Dates

First Submitted

March 30, 2025

First Submitted That Met QC Criteria

April 11, 2025

First Posted (Actual)

April 18, 2025

Study Record Updates

Last Update Posted (Actual)

June 4, 2025

Last Update Submitted That Met QC Criteria

May 31, 2025

Last Verified

May 1, 2025

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Morbid Obesity

Clinical Trials on Controlled exercise with telerehabilitation

Subscribe